RT Journal Article
SR Electronic
T1 SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.19.21249840
DO 10.1101/2021.01.19.21249840
A1 Dami A. Collier
A1 Anna De Marco
A1 Isabella A.T.M. Ferreira
A1 Bo Meng
A1 Rawlings Datir
A1 Alexandra C. Walls
A1 Steven A. Kemp S
A1 Jessica Bassi
A1 Dora Pinto
A1 Chiara Silacci Fregni
A1 Siro Bianchi
A1 M. Alejandra Tortorici
A1 John Bowen
A1 Katja Culap
A1 Stefano Jaconi
A1 Elisabetta Cameroni
A1 Gyorgy Snell
A1 Matteo S. Pizzuto
A1 Alessandra Franzetti Pellanda
A1 Christian Garzoni
A1 Agostino Riva
A1 The CITIID-NIHR BioResource COVID-19 Collaboration
A1 Anne Elmer
A1 Nathalie Kingston
A1 Barbara Graves
A1 Laura E McCoy
A1 Kenneth GC Smith
A1 John R. Bradley
A1 J James Thaventhiran
A1 L Lourdes Ceron-Gutierrez
A1 Gabriela Barcenas-Morales
A1 Herbert W. Virgin
A1 Antonio Lanzavecchia
A1 Luca Piccoli
A1 Rainer Doffinger
A1 Mark Wills
A1 David Veesler
A1 Davide Corti
A1 Ravindra K. Gupta
YR 2021
UL http://medrxiv.org/content/early/2021/02/02/2021.01.19.21249840.abstract
AB SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 mutations found in the B.1.1.7 Spike protein. The vaccine sera exhibited a broad range of neutralizing titres against the wild-type pseudoviruses (<1:4 to 3449) that were reduced against B.1.1.7 variant by 3.85 fold (IQR 2.68-5.28). This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralization was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 outof 29), but not in neutralizing mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background led to a further loss of neutralizing activity by vaccine-elicited antibodies over that conferred by the B.1.1.7 mutations alone. Further work is needed to establish the impact of these observations on protective vaccine efficacy in the context of the evolving B.1.1.7 lineage that will likely acquire E484K.Competing Interest StatementA.D.M., J.B., D.P., C.S.F., S.B., K.C., N.S., E.C., G.S., S.J., A.L., H.W.V., M.S.P., L.P. and D.C. are employees of Vir Biotechnology and may hold shares in Vir Biotechnology. H.W.V. is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work or is performing related work. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. RKG has received consulting fees from UMOVIS Lab, Gilead and ViiV.Funding StatementThis research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical ScienceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee 17 EE 0025.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author on request